RYTM logo

RHYTHM PHARMACEUTICALS INC

RYTMNASDAQ
πŸ† #923 by market capEarnings Feb 24 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track RYTM
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$7.79B
Small Cap
πŸ“ˆRevenue Growth (YoY)
61.0%
High Growth
πŸ“ŠGross Margin
72.8%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
27.7x
Expensive
Otter Score
72
Strong
No chart data available for RYTM.

Trading Snapshot

Day Range
β€”
52-Week Range
$74.50 – $122.20
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
68.8M
Next Earnings
2027-02-24

Fundamentals Snapshot

Annual Revenue
$190M
Last Q Revenue
$92M
P/E Ratio
β€”
P/S Ratio
27.7x
EPS (TTM)
$-2.85
Dividend Yield
β€”
Dilution (1yr)
+8.6%
RYTM logo

RHYTHM PHARMACEUTICALS INC

RYTM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$190Mβ–² +45.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
89.7%β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$192Mβ–Ό βˆ’27.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$117Mβ–² +2.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
66.9Mβ–² +8.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$50Mβ–Ό βˆ’$35M YoY
StockOtter Β· stockotter.space

About RHYTHM PHARMACEUTICALS INC

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and AlstrΓΆm syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100
Analyst data unavailable.

Latest News & Updates

News unavailable.